Ryoko Yamada

1.8k total citations
50 papers, 911 citations indexed

About

Ryoko Yamada is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Ryoko Yamada has authored 50 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hepatology, 26 papers in Epidemiology and 10 papers in Surgery. Recurrent topics in Ryoko Yamada's work include Hepatitis C virus research (20 papers), Liver Disease Diagnosis and Treatment (18 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). Ryoko Yamada is often cited by papers focused on Hepatitis C virus research (20 papers), Liver Disease Diagnosis and Treatment (18 papers) and Hepatocellular Carcinoma Treatment and Prognosis (13 papers). Ryoko Yamada collaborates with scholars based in Japan, United States and United Kingdom. Ryoko Yamada's co-authors include Tetsuo Takehara, Tomohide Tatsumi, Takahiro Kodama, Ryotaro Sakamori, Hayato Hikita, Minoru Shigekawa, Yuki Tahata, Yuki Makino, Hidetoshi Eguchi and Takayuki Yakushijin and has published in prestigious journals such as Journal of Clinical Investigation, Gastroenterology and PLoS ONE.

In The Last Decade

Ryoko Yamada

46 papers receiving 902 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryoko Yamada Japan 17 430 423 245 174 122 50 911
Kolade M. Agboola United States 9 516 1.2× 357 0.8× 340 1.4× 78 0.4× 105 0.9× 20 926
Hidetaka Shibata Japan 18 498 1.2× 409 1.0× 406 1.7× 142 0.8× 82 0.7× 54 1.1k
Kunimaro Furuta Japan 17 405 0.9× 298 0.7× 293 1.2× 55 0.3× 90 0.7× 32 776
Yuping Chen China 15 504 1.2× 265 0.6× 681 2.8× 263 1.5× 107 0.9× 41 1.2k
Koujiro Takase Japan 16 260 0.6× 257 0.6× 494 2.0× 143 0.8× 118 1.0× 35 961
Victoria L. Gadd United Kingdom 14 490 1.1× 415 1.0× 194 0.8× 65 0.4× 156 1.3× 22 915
Agnieszka Adamek Poland 12 217 0.5× 185 0.4× 305 1.2× 107 0.6× 57 0.5× 33 767
Andrew Scanga United States 10 295 0.7× 383 0.9× 156 0.6× 65 0.4× 44 0.4× 19 683
Albert Geerts Belgium 13 349 0.8× 458 1.1× 306 1.2× 99 0.6× 103 0.8× 19 884
Tamara Severi Belgium 9 238 0.6× 287 0.7× 198 0.8× 99 0.6× 34 0.3× 10 604

Countries citing papers authored by Ryoko Yamada

Since Specialization
Citations

This map shows the geographic impact of Ryoko Yamada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryoko Yamada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryoko Yamada more than expected).

Fields of papers citing papers by Ryoko Yamada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryoko Yamada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryoko Yamada. The network helps show where Ryoko Yamada may publish in the future.

Co-authorship network of co-authors of Ryoko Yamada

This figure shows the co-authorship network connecting the top 25 collaborators of Ryoko Yamada. A scholar is included among the top collaborators of Ryoko Yamada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryoko Yamada. Ryoko Yamada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Myojin, Yuta, Takahiro Kodama, Ryotaro Sakamori, et al.. (2022). Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers. 14(4). 883–883. 57 indexed citations
2.
Maesaka, Kazuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2022). Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatology Research. 52(7). 630–640. 31 indexed citations
3.
4.
Murai, Kazuhiro, Takahiro Kodama, Hayato Hikita, et al.. (2022). Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy. Hepatology Communications. 6(9). 2474–2487. 9 indexed citations
5.
Maesaka, Kazuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2021). Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment. Hepatology Research. 51(5). 517–527. 3 indexed citations
6.
Hikita, Hayato, Kazuhiro Murai, Tasuku Nakabori, et al.. (2021). Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus–Infected Hepatocytes During Interferon Administration. Hepatology Communications. 6(2). 281–296. 4 indexed citations
7.
Kodama, Takahiro, Sadatsugu Sakane, Olivier Govaere, et al.. (2021). Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology. 74(5). 2452–2466. 99 indexed citations
8.
Maesaka, Kazuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2021). Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatology Research. 52(3). 298–307. 27 indexed citations
9.
Tamura, Takeshi, Takahiro Kodama, Katsuhiko Sato, et al.. (2021). Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation. Journal of Clinical Investigation. 131(13). 23 indexed citations
10.
Sakane, Sadatsugu, Hayato Hikita, Yuta Myojin, et al.. (2021). White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in Mice. Cellular and Molecular Gastroenterology and Hepatology. 12(5). 1683–1699. 38 indexed citations
11.
Maesaka, Kazuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2020). Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension. Hepatology Research. 50(9). 1091–1100. 2 indexed citations
12.
Murai, Kazuhiro, Hayato Hikita, Yugo Kai, et al.. (2020). Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Scientific Reports. 10(1). 941–941. 17 indexed citations
13.
14.
Tahata, Yuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2020). Clinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatology Research. 50(10). 1118–1127. 13 indexed citations
15.
Maesaka, Kazuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2020). Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma. Hepatology Research. 50(11). 1275–1283. 4 indexed citations
16.
Maesaka, Kazuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2019). Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatology Research. 50(3). 365–373. 12 indexed citations
17.
Kodama, Takahiro, Yuta Myojin, Ryoko Yamada, et al.. (2019). CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. Cancers. 11(9). 1362–1362. 26 indexed citations
18.
Sasaki, Yōichi, Ryotaro Sakamori, Ryoko Yamada, et al.. (2019). Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation. Hepatology Research. 49(11). 1357–1361. 4 indexed citations
19.
Tahata, Yuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2019). Hepatocellular carcinoma occurrence does not differ between interferon‐based and interferon‐free treatment with liver histological assessment. Hepatology Research. 50(3). 313–320. 4 indexed citations
20.
Makino, Yuki, Hayato Hikita, Takahiro Kodama, et al.. (2018). CTGF Mediates Tumor–Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression. Cancer Research. 78(17). 4902–4914. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kolade M. Agboola Breakdown of academic impact, for papers by Hidetaka Shibata Breakdown of academic impact, for papers by Kunimaro Furuta Breakdown of academic impact, for papers by Yuping Chen Breakdown of academic impact, for papers by Koujiro Takase Breakdown of academic impact, for papers by Victoria L. Gadd Breakdown of academic impact, for papers by Agnieszka Adamek Breakdown of academic impact, for papers by Andrew Scanga Breakdown of academic impact, for papers by Albert Geerts Breakdown of academic impact, for papers by Tamara Severi
Rankless by CCL
2026